Lansoprazole

Lansoprazole


Systematic (IUPAC) name
(RS)-2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole
Clinical data
Trade names	Prevacid
AHFS/Drugs.com	monograph
MedlinePlus	a695020
Licence data	US FDA:link
Pregnancy cat.	B3(AU) B(US)
Legal status	OTC (US) Rx Only
Routes	Oral, IV
Pharmacokinetic data
Bioavailability	80% or more
Protein binding	97%
Metabolism	Hepatic (CYP3A4- and CYP2C19-mediated)
Half-life	1–1.5 hours
Excretion	Renal and fecal
Identifiers
CAS number	103577-45-3^Y
ATC code	A02BC03
PubChem	CID 3883
DrugBank	APRD00077
ChemSpider	3746^Y
UNII	0K5C5T2QPG^Y
KEGG	D00355^Y
ChEBI	CHEBI:6375^Y
ChEMBL	CHEMBL480^Y
Chemical data
Formula	C₁₆H₁₄F₃N₃O₂S
Mol. mass	369.363 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)^Y Key:MJIHNNLFOKEZEW-UHFFFAOYSA-N^Y
N(what is this?) (verify)

Lansoprazole ( /lænˈsoʊprəzoʊl/ lan-soh-prə-zohl; INN) is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid. It is manufactured by a number of companies worldwide under several brand names (some brand names include: Prevacid, Helicid, Zoton, Inhibitol, Monolitum). It was first approved by the U.S. Food and Drug Administration (FDA) in 1995.^[1]

Prevacid patent protection expired on November 10, 2009.^[2]^[3] As a result, prescription Lansoprazole is now available in the form of a generic drug. As of November 12, 2009 (2009 -11-12)^[update], Lansoprazole is available over-the-counter (OTC) in the U.S. in a 15 mg dose marketed by Novartis as Prevacid 24HR.^[4]^[5]^[6]

Main article: Proton-pump inhibitor

Lansoprazole is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available.^[7] Lansoprazole is a racemate [1:1-mixture of the enantiomers dexlansoprazole (Kapidex) and levolansoprazole].^[8] Dexlanprantazole is an enantiomerically pure active ingredient of a commercial drug as a result of the 'enantiomeric shift'.

Lansoprazole's plasma elimination half-life is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression). The mean plasma elimination half-life is 1.5 hours,^[9] and the effects of the drug last for over 24 hours after it has been used for 1 day or more.^[10] Lansoprazole, 30 mg administered nasogastrically, effectively controls intragastric pH and is an alternative to i.v. pantoprazole in patients who are unable to swallow solid dosage formulations.^[11]

1 Indications
2 Drug interactions
3 Side effects
4 Brand names
5 References
6 External links

Indications

Lansoprazole is indicated for:

Treatment of ulcers of the stomach and duodenum, and NSAID-induced ulcers
Treatment of gastroesophageal reflux disease (GERD) (also known as acid reflux disease)
Treatment of Zollinger-Ellison Syndrome
Adjunctive treatment of Helicobacter pylori infection, alongside antibiotics

Drug interactions

PPIs reduce absorption of antifungals (itraconazole and ketoconazole) ^[12] and possibly increase Digoxin in plasma
Increases plasma concentrations of Cilostazol (risk of toxicity)
Absorption of lansoprazole possibly reduced by:
- sucralfate
- ampicillin
- bisacodyl
- delavirdine
- fluvoxamine
- iron salts
- voriconazole
- aminophylline and theophylline
- astemizole

Using Prevacid for Treating H. Pylori Infections Treatment to kill Helicobacter pylori (H. pylori) involves using two other drugs besides Prevacid. This treatment is known as "triple therapy." Triple therapy to kill H. pylori involves taking Prevacid 30 mg twice a day, plus amoxicillin 1,000 mg (twice daily) and clarithromycin 500 mg (twice daily). All three medications are taken for 10 or 14 days.

Side effects

Infrequent: dry mouth, insomnia, drowsiness, blurred vision, rash, pruritus
Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema, hypersensitivity reactions (including bronchospasm, urinary, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis, blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions^[13] including (erythroderma^[14] Stevens–Johnson syndrome, toxic epidermal necrolysis, bullous eruption)
Severe: Gastro-intestinal disturbances (such as nausea 1.3%, abdominal pain 2.1%, diarrhea 3.8%).^[9]

Proton-pump inhibitors may be associated with a greater risk of hip fractures,^[15] Clostridium difficile-associated diarrhea.^[16] Patients are frequently administered the drugs in intensive care as a protective measure against ulcers, but this use is also associated with a 30% increase in occurrence of pneumonia.^[17]